You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南京醫藥(600713.SH):南藥湖北擬設立兩家子公司 承接南藥湖北區域性業務
格隆匯 08-17 16:52

格隆匯8月17日丨南京醫藥(600713.SH)公佈,為進一步健全公司在湖北省內的市場網絡佈局,發揮南藥湖北內生及外延發展動能,順應國家醫改相關政策導向,公司控股子公司南藥湖北:

(1)與騰正至康共同出資800萬元設立南京醫藥咸寧有限公司(以下簡稱“南藥咸寧”,暫定名)。其中南藥湖北出資408萬元,佔南藥咸寧註冊資本的51%;騰正至康出資392萬元,佔南藥咸寧註冊資本的49%。

(2)與監利瑞康共同出資800萬元設立南京醫藥荊州有限公司(以下簡稱“南藥荊州”,暫定名)。其中南藥湖北出資408萬元,佔南藥荊州註冊資本的51%;監利瑞康出資392萬元,佔南藥荊州註冊資本的49%。

以上兩家公司,南藥湖北合計出資816萬元。南藥咸寧立足咸寧城區,覆蓋咸寧地市。南藥荊州立足監利縣,覆蓋荊州地區。兩家新公司將成為南藥湖北區域性業務承接平台,努力建成全終端全覆蓋高佔有的區域行業龍頭企業。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account